Why the study?
Does recent management (2011) improve in-hospital, 30-day, and 1-year mortality compared to 2005 management in PCI-treated STEMI patients?
Does recent management (2011) improve in-hospital, 30-day, and 1-year mortality compared to 2005 management in PCI-treated STEMI patients?
Changes in STEMI management between 2005 and 2011 improved in-hospital mortality but did not translate to 30-day or 1-year survival benefits, highlighting a need for better adherence to guideline-recommended pharmacotherapy.
Answers are grounded in this paper and cite their sources.
In-hospital mortality gains in STEMI PCI did not extend to 30-day or 1-year survival; leaves open need for better post-discharge pharmacotherapy adherence.
BACKGROUND: Nowadays, the majority of patients with myocardial infarction with ST-segment elevation (STEMI) are treated with primary percutaneous coronary interventions (PCI). In recent years, there have been ongoing improvements in PCI techniques, devices and concomitant pharmacotherapy. However, reports on further mortality reduction among PCI-treated STEMI patients remain inconclusive. The aim of this study was to compare changes in management and mortality in PCI-treated STEMI patients between 2005 and 2011 in a real-life setting. METHODS: Data on 79,522 PCI-treated patients with STEMI from Polish Registry of Acute Coronary Syndromes (PL-ACS) admitted to Polish hospitals between 2005 and 2011 were analyzed. First, temporal trends of in-hospital management in men and women were presented. In the next step, patients from 2005 and 2011 were nearest neighbor matched on their propensity scores to compare in-hospital, 30-day and 1-year mortality rates and in-hospital management strategies and complications. RESULTS: Some significant changes were noted in hospital management including shortening of median times from admission to PCI, increased use of drug-eluting stents, potent antiplatelet agents but also less frequent use of statin, beta-blockers and angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. There was a strong tendency toward preforming additional PCI of non-infarct related arteries, especially in women. After propensity score adjustment there were significant changes in inhospital but not in 30-day or 1-year mortality rates between 2005 and 2011. The results were similar in men and women. CONCLUSIONS: There were apparent changes in management and significant in-hospital mortality reductions in PCI-treated STEMI patients between 2005 and 2011. However, it did not result in 30-day or 1-year survival benefit at a population level. There may be room for improvement in the use of guideline-recommended pharmacotherapy.
No takes yet. Share an insight, caveat, or question.
Zandecki et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: